Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7818940 | 0.86 | SLC6A2 (0.54) | HDAC6HDAC1HDAC8SLC6A2SLC6A4 | |
| SCHEMBL18768607 | 0.84 | SLC6A2 (0.47) | RAD51HDAC6HDAC1HDAC8SLC6A2 | |
| SCHEMBL16874867 | 0.84 | CCR1 (0.42) | CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL18740427 | 0.84 | RAD51 (0.41) | RAD51HDAC6HDAC1HDAC8SLC6A2 | |
| SCHEMBL892162 | 0.83 | PTPN1 (0.44) | RAD51HDAC6HDAC1HDAC8SLC6A2 | |
| SCHEMBL8606629 | 0.81 | MCHR1 (0.41) | HDAC6HDAC1HDAC8CCNA2CDK2 | |
| SCHEMBL7819893 | 0.80 | SLC6A2 (0.50) | HDAC6HDAC1HDAC8SLC6A2SLC6A4 | |
| SCHEMBL16422794 | 0.79 | FPR2 (0.48) | CCNA2CDK2CCNA1 | |
| SCHEMBL21142409 | 0.79 | MCHR1 (0.42) | SLC6A2SLC6A4MCHR1 | |
| SCHEMBL18740383 | 0.79 | MCHR1 (0.42) | SLC6A2SLC6A4MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961229-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200071304-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071304-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | RAD51 3463/4885HDAC6 475/4885HDAC1 545/4885 |
| US-10961229-B2 | Selective NR2B antagonists | GRIN2B, GRIN2A, GRIN3A | RAD51 3463/4885HDAC6 475/4885HDAC1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.